EcoDrugPlus

Tubulin, Beta 5

Ensembl ID : ENSLCAG00010004440
Gene Symbol: TUBB5
1 Cross references
160 Possible Orthologues:

Tubulin, Beta 6 Class V

Ensembl ID : ENSLCAG00010007661
Gene Symbol: TUBB6
4 Cross references
141 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSLCAG00010007650
Gene Symbol: TP53
3 Cross references
232 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSLCAG00010021647
Gene Symbol: TYR
1 Cross references
202 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSLCAG00010026011
Gene Symbol: TYR
4 Cross references
198 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSLCAG00010018068
Gene Symbol: LOC108875328
4 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSLCAG00010000914
Gene Symbol: TYK2
4 Cross references
195 Possible Orthologues:

Ubiquitin-Conjugating Enzyme E2 E2

Ensembl ID : ENSLCAG00010003046
Gene Symbol: LOC108900280
4 Cross references
236 Possible Orthologues:

Utrophin

Ensembl ID : ENSLCAG00010006859
Gene Symbol: UTRN
1 Cross references
270 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSLCAG00010016746
Gene Symbol: LOC108875379
4 Cross references
207 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSLCAG00010007346
Gene Symbol: AKT2
2 Cross references
210 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSLCAG00010010265
Gene Symbol: AKT2L
1 Cross references
161 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).